BioSpace News Archive

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a sponsored research agreement with Boston Children’s Hospital to study TNX-15001 for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in animals.

AnPac Bio-Medical Science Co., Ltd. announced that the Company has formed a wholly-owned subsidiary Fresh2 Technology Inc in the State of Delaware on October 4, 2022 in order to establish the company’s new product line of business-to-business food trade and delivery platform for local restaurants and supermarkets, a combination of the China’s food distribution strategies and North America’s growing Asian food market.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company has reached a mutual understanding with nine investors.

Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant ™ probes.

Novo Nordisk Research Centre China and ATLATL jointly announce the winners of EntreStar program.

Diadem SpA presented clinical data at the 15th Clinical Trials on Alzheimer’s Disease conference highlighting the accuracy and clinical utility of its AlzoSure® Predict prognostic blood test for Alzheimer’s Disease, setting the stage for commercialization in the U.S. beginning in 2023.

Vicore Pharma Holding AB, a pioneer in the development of angiotensin II type 2 receptor agonists, launched the pivotal phase of COMPANION, the first clinical investigation of a digital cognitive behavioral therapy for patients with pulmonary fibrosis.

Ellipses Pharma Limited will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm in advanced breast cancer at the San Antonio Breast Cancer Symposium in San Antonio, Texas on Tuesday, 6 December from 5:00pm to 6:15pm CST.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for Travelan®.

HilleVax, Inc. (Nasdaq: HLVX) today reported results from a prespecified immunogenicity analysis of the 203 subjects enrolled in the run-in cohort of NEST-IN1 (Norovirus Efficacy and Safety Trial for INfants), the company’s ongoing Phase 2b trial for HIL-214, its investigational virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe norovirus-related acute gastroenteritis (AGE) in infants.